PUS7介导的TGFBI假尿苷化驱动肺动脉高压血管重塑
该研究在肺动脉高压(PH)患者肺组织中绘制了首个单碱基分辨率假尿苷(Ψ)图谱,发现PUS7在患者肺组织和低氧肺动脉内皮细胞中显著上调。PUS7通过催化TGFBI mRNA第688位Ψ修饰稳定TGFBI,激活PI3K-AKT通路,形成HIF-2α/PUS7/TGFBI/PI3K-AKT正反馈环路驱动PH;遗传或药理抑制PUS7可改善PH,而过表达则加重病情。
要点
- PUS7在PH患者肺组织和低氧内皮细胞中显著上调,是PH的表观遗传驱动因子。
- PUS7催化TGFBI mRNA 688位Ψ修饰,稳定TGFBI并激活PI3K-AKT通路。
- HIF-2α/PUS7/TGFBI/PI3K-AKT正反馈环路驱动PH,抑制PUS7可改善PH。
核心结论
- PUS7介导的假尿苷化通过HIF-2α/PUS7/TGFBI/PI3K-AKT轴驱动PH,PUS7是潜在治疗靶点。
研究设计与样本
- 研究采用亚硫酸氢盐诱导缺失测序在PH患者肺组织中绘制单碱基分辨率Ψ图谱。
- 在低氧肺动脉内皮细胞、PH患者肺组织和SU5416-低氧啮齿类模型中分析PUS7表达。
- 通过基因操作(PUS7缺陷细胞、AAV血清型介导过表达、内皮细胞特异性敲低和杂合敲除小鼠)及NSC107512药理抑制研究PUS7功能。
主要发现
- 亚硫酸氢盐诱导缺失测序揭示PH患者肺组织全局Ψ失调。
- PUS7在PH患者肺组织和低氧肺动脉内皮细胞中上调最显著。
- 基因敲低和NSC107512药理抑制均改善PH,而AAV血清型介导的PUS7过表达加剧疾病进展。
- RNA免疫沉淀测序和突变研究表明PUS7结合并催化TGFBI mRNA第688位Ψ,稳定TGFBI并激活PI3K-AKT通路。
- HIF-2α直接结合PUS7启动子,建立HIF-2α/PUS7/TGFBI/PI3K-AKT正反馈环路驱动PH发病。
临床怎么用
- PUS7可作为PH的表观遗传治疗靶点,药理抑制PUS7(如NSC107512)在模型中改善PH。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pulmonary hypertension (PH) is a life-threatening cardiovascular disorder characterized by irreversible pulmonary vascular remodeling and poor prognosis. RNA pseudouridylation, the most evolutionarily conserved RNA epigenetic modification, and its catalytic enzyme pseudouridine synthase 7 (PUS7) remained uncharacterized in PH, representing a major gap in the understanding of the epigenetic pathogenesis of the disease. METHODS: We generated the first single-base resolution pseudouridine (Ψ) landscape in lung tissues of patients with PH using bisulfite-induced deletion sequencing. PUS7 expression was analyzed in hypoxic pulmonary artery endothelial cells, the lung tissues of patients with PH, and SU5416-hypoxia rodent model. The functional roles of PUS7 were investigated through genetic manipulation (PUS7-deficiency cells, adeno-associated virus serotype-mediated overexpression, endothelial cell-specific knockdown, and heterozygous knockout mice) and pharmacological inhibition with NSC107512. RESULTS: Bisulfite-induced deletion sequencing revealed global Ψ dysregulation in the lung tissues of patients with PH. Among PUS family members, PUS7 was the most markedly upregulated in these tissues and in the hypoxic pulmonary artery endothelial cells. Both gene knockdown and pharmacological inhibition with NSC107512 ameliorated PH, whereas adeno-associated virus serotype-mediated PUS7 overexpression exacerbated disease progression. RNA immunoprecipitation sequencing and mutagenesis studies demonstrated that PUS7 bound to and catalyzed Ψ at position 688 of TGFBI (transforming growth factor β-induced protein) mRNA, thereby stabilizing TGFBI and activating phosphatidylinositol 3-kinase-protein kinase B signaling pathway. Furthermore, hypoxia-inducible factor 2α bound directly to the PUS7 promoter, establishing a hypoxia-inducible factor 2α/PUS7/TGFBI/phosphatidylinositol 3-kinase-protein kinase B positive feedback loop that drives PH pathogenesis. CONCLUSIONS: PUS7-mediated pseudouridylation serves as a novel epigenetic driver of PH through the hypoxia-inducible factor 2α/PUS7/TGFBI/phosphatidylinositol 3-kinase-protein kinase B axis, positioning PUS7 as a promising therapeutic target for this devastating disease.
引用
- Zhang J, Li Y, He M, et al. PUS7-Mediated Pseudouridylation of TGFBI Drives Vascular Remodeling in Pulmonary Hypertension. Circulation. 2026. PMID: 42677488. doi:10.1161/CIRCULATIONAHA.126.080714
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。